I find this an interesting paper because its one of the few instances of intravenous rapamycin delivery I’ve come across. It seems like an approach like this may be valuable to investigate for longevity at some point.
Intravenous sirolimus (albumin bound, SRL-HSA) was well tolerated and elicited durable responses in patients with malignant perivascular epithelioid cell tumors (PEComa), according to findings from a phase 1b trial (NCT05625919) presented during the 2025 ESMO Sarcoma and Rare Cancers Congress.1
Reference
Niu X, Zhang X, Guo J, et al. 66MO Intravenous sirolimus (albumin bound, SRL-HSA) in malignant perivascular epithelioid cell tumors (PEComas): A multicenter, open label, phase Ib trial. ESMO Open. 2025;10(suppl 3):104380. doi:10.1016/j.esmoop.2025.104380
1 Like
AnUser
#2
The albumin binding seems to create some superior characteristics, sold as Fyarro:
Nonclinical studies demonstrated significant pharmacodynamic improvement over oral mTOR inhibitors, including1,3:*
-
Enhanced bioavailability
-
Higher tumor drug concentrations
-
Increased mTOR target suppression
-
Stronger antitumor activity
-
Nonclinical data may not correlate with clinical outcomes.
AUC=area under the curve; IV=intravenous; mTOR=mechanistic target of rapamycin; UMUC3=University of Michigan-Urothelial Carcinoma-3.
1 Like
约瑟夫
#3
Not New…
This was posted over two years ago…
Was around $7,000.00 per 100mg
Do not see many purchasing this for longevity use.
1 Like
